Literature DB >> 16023596

The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase.

Wenyi Wei1, Jianping Jin, Susanne Schlisio, J Wade Harper, William G Kaelin.   

Abstract

The c-Jun and c-Myc oncogenic transcription factors are highly unstable proteins due to polyubiquitination. Similar to c-Myc, we report here that phosphorylation of c-Jun by GSK3 creates a high-affinity binding site for the E3 ligase Fbw7, which targets c-Jun for polyubiquitination and proteasomal degradation. In keeping with this, we found that c-Jun levels were inversely related to GSK3 activity in mammalian cells that had entered the cell cycle. Importantly, phosphorylation of c-Jun by GSK3 requires a priming phosphorylation event at Ser-243. Ser-243 is mutated to phenylalanine in v-Jun and allows it to escape recognition by Fbw7. These findings explain the enhanced stability and oncogenicity of v-Jun relative to its cellular counterpart and reveal that GSK3 and Fbw7 coordinately regulate c-Jun and c-Myc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16023596     DOI: 10.1016/j.ccr.2005.06.005

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  204 in total

1.  Expression of the novel human gene, UBE2Q1, in breast tumors.

Authors:  Atefeh Seghatoleslam; Mohsen Nikseresht; Sayed Mohammad Shafiee; Ahmad Monabati; Mohammad Mehdi Namavari; Abdolrassul Talei; Akbar Safaei; Ali Akbar Owji
Journal:  Mol Biol Rep       Date:  2011-12-14       Impact factor: 2.316

2.  GSK-3β regulates cell growth, migration, and angiogenesis via Fbw7 and USP28-dependent degradation of HIF-1α.

Authors:  Daniela Flügel; Agnes Görlach; Thomas Kietzmann
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

3.  Identification of a co-activator that links growth factor signalling to c-Jun/AP-1 activation.

Authors:  Clare C Davies; Atanu Chakraborty; Filippo Cipriani; Katharina Haigh; Jody J Haigh; Axel Behrens
Journal:  Nat Cell Biol       Date:  2010-09-19       Impact factor: 28.824

4.  The repressing function of the oncoprotein BCL-3 requires CtBP, while its polyubiquitination and degradation involve the E3 ligase TBLR1.

Authors:  Aurore Keutgens; Kateryna Shostak; Pierre Close; Xin Zhang; Benoît Hennuy; Marie Aussems; Jean-Paul Chapelle; Patrick Viatour; André Gothot; Marianne Fillet; Alain Chariot
Journal:  Mol Cell Biol       Date:  2010-06-14       Impact factor: 4.272

5.  The ubiquitin ligase Fbxw7 controls adipocyte differentiation by targeting C/EBPalpha for degradation.

Authors:  Maria T Bengoechea-Alonso; Johan Ericsson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

6.  DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.

Authors:  Naoe Taira; Rei Mimoto; Morito Kurata; Tomoko Yamaguchi; Masanobu Kitagawa; Yoshio Miki; Kiyotsugu Yoshida
Journal:  J Clin Invest       Date:  2012-02-06       Impact factor: 14.808

7.  Acetylation-dependent regulation of Skp2 function.

Authors:  Hiroyuki Inuzuka; Daming Gao; Lydia W S Finley; Wen Yang; Lixin Wan; Hidefumi Fukushima; Y Rebecca Chin; Bo Zhai; Shavali Shaik; Alan W Lau; Zhiwei Wang; Steven P Gygi; Keiko Nakayama; Julie Teruya-Feldstein; Alex Toker; Marcia C Haigis; Pier Paolo Pandolfi; Wenyi Wei
Journal:  Cell       Date:  2012-07-06       Impact factor: 41.582

Review 8.  GSK3 signalling in neural development.

Authors:  Eun-Mi Hur; Feng-Quan Zhou
Journal:  Nat Rev Neurosci       Date:  2010-08       Impact factor: 34.870

Review 9.  Targeting the ubiquitin pathway for cancer treatment.

Authors:  Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-12-04

10.  Differential regulation of FBXW7 isoforms by various stress stimuli.

Authors:  Ronit Vogt Sionov; Efrat Netzer; Eitan Shaulian
Journal:  Cell Cycle       Date:  2013-09-24       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.